MERIDEN, Conn. and SCOTTSDALE, Ariz., Aug. 19, 2014 /PRNewswire/ -- Protein Sciences Corporation and Passport Health announced today that Flublok® influenza vaccine will be available this fall at all 230+ Passport Health locations across the United States. In addition, all employers who arrange their influenza vaccination clinics through Passport Health will be able to request Flublok.
"We created Flublok to save lives and our obligation is to make it readily available to those who need or want it," said Dr. Manon Cox, President and CEO of Protein Sciences. "It is disappointing to hear that people have been asking for it by name only to be told that it's not available." She continued, "We are delighted that our agreement with Passport Health will help change that."
"We are proud to bring this modern vaccine to our patients," said Fran Lessans, CEO and Founder of Passport Health. She added, "Flublok is the perfect choice for those seeking pure, safe and effective influenza protection."
Passport Health has set up an educational page on their website to raise awareness about Flublok. To make an individual appointment to get vaccinated in a Passport Health clinic, please visit the company website at www.passporthealthusa.com. Employers who would like to schedule an onsite Flublok event at their workplace should email firstname.lastname@example.org, or visit this webpage: http://www.passporthealthusa.com/employer-solutions/on-site-flu-clinics/ so that Passport Health's sales and client services staff can coordinate the event.
About Protein Sciences
Protein Sciences is a vaccine development and protein production company that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceuticals.
Flublok, the world's first recombinant protein-based vaccine for the prevention of seasonal influenza disease, was approved by FDA in January 2013. Flublok is the only flu vaccine made in a 100% egg-free system using modern cell culture technology, making it unnecessary to use an infectious influenza virus or antibiotics in manufacturing. Flublok is highly purified and does not contain any preservatives (e.g., thimerosal, a mercury derivative), egg proteins, gelatin or latex. In addition, Flublok is triple the strength of conventional influenza vaccines. Flublok is a perfect copy of the virus coat and is not subject to the egg-adapted mutations associated with low vaccine effectiveness (see Skowronski et al. (2014) PLOS ONE 9(3), e92153). We have filed for FDA approval of Flublok for ages 50 and above and expect to receive approval in time for the 2014/15 influenza season.
Healthcare professionals can order Flublok by contacting FFF Enterprises at 800-843-7477 or ASD Specialty Healthcare at 866-281-4FLU.
About Passport Health:
Passport Health is the largest and leading provider of travel medicine and vaccination services in the North America. With over 230 clinic locations, 20+ years of experience, a commitment to first class medical care, and rigorously trained medical staff, Passport Health sets the immunization industry standard. Passport Health's core services have grown from travel medicine to include on-site flu clinics, specialty physical exams, routine immunizations, and vaccination records management solutions for public and private sector clients of all sizes.
Flublok Safety Information
Flublok is approved for people 18-49 years old to prevent influenza disease. The most common side effect from Flublok is pain at the site of injection. Other side effects may occur and include fatigue, headache and muscle aches.
Flublok should not be administered to anyone with a severe allergic reaction (e.g., anaphylaxis) to any vaccine component.
Tell the doctor if you have ever experienced Guillain-Barre syndrome (severe muscle weakness) within 6 weeks of receipt of a previous dose of influenza vaccine. If you notice any other problems or symptoms following vaccination, please contact your healthcare professional immediately. Vaccination with Flublok may not protect all individuals.
SOURCE Protein Sciences Corporation